RecruitingNCT06458504

Viral Infection of HSPC Impacts Hematopoiesis

Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

45 participants

Start Date

Oct 25, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • HIV patients :
  • HIV-positive patients with a negative or positive viral load.
  • managed at Ambroise Paré Hospital.
  • patients with a bone marrow biopsy or myelogram performed as part of their care.
  • Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.
  • Management at Ambroise Paré Hospital.

Exclusion Criteria1

  • \-

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Hematology and interne medicine department, Ambroise Paré hospital - APHP

Boulogne-Billancourt, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06458504


Related Trials